Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.45B | 5.59B | 10.01B | 8.25B | 2.99B |
Gross Profit | 1.87B | 4.41B | 7.60B | 5.80B | 866.85M |
EBITDA | -3.78B | -714.00M | 2.20B | 1.11B | -4.44B |
Net Income | -3.83B | -1.96B | 1.18B | 2.03B | -4.09B |
Balance Sheet | |||||
Total Assets | 4.97B | 8.17B | 10.43B | 8.45B | 6.27B |
Cash, Cash Equivalents and Short-Term Investments | 3.96B | 6.52B | 6.28B | 3.86B | 3.85B |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Total Liabilities | 770.77M | 960.33M | 1.93B | 1.71B | 1.62B |
Stockholders Equity | 4.20B | 7.21B | 8.51B | 6.75B | 4.66B |
Cash Flow | |||||
Free Cash Flow | -3.44B | -427.48M | 1.57B | 76.20M | -4.27B |
Operating Cash Flow | -3.42B | -194.69M | 1.61B | 140.04M | -4.12B |
Investing Cash Flow | -3.96M | -376.70M | -47.13M | -70.85M | -160.31M |
Financing Cash Flow | 708.47M | 680.16M | 627.99M | -71.92M | 4.22B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | ¥12.22T | 30.91 | 21.48% | 1.44% | 17.96% | 25.65% | |
72 Outperform | ¥2.66T | 52.12 | 3.22% | 5.01% | 19.25% | 294.48% | |
68 Neutral | ¥6.77T | 23.28 | 17.60% | 1.65% | 17.77% | 49.34% | |
67 Neutral | ¥1.18T | 25.52 | 5.34% | 3.83% | 6.42% | 10.82% | |
65 Neutral | ¥354.70B | 11.38 | -2.99% | 2.49% | 11.76% | -10.21% | |
62 Neutral | $6.86T | 63.30 | 1.50% | 4.55% | 7.45% | -25.77% | |
51 Neutral | ¥7.70B | ― | ― | -56.12% | -73.82% |
SymBio Pharmaceuticals Limited reported a significant decline in financial performance for the fiscal year 2024, with net sales falling by 56.1% and a substantial increase in net loss compared to the previous year. The company continues to face challenges, including a decrease in total assets and cash equivalents, while planning a new subsidiary in the USA, which may impact its future operations and market positioning.